Oct 18, 2017
Watson for Oncology is IBM’s supercomputer solution, which claims to help “…doctors out-think cancer…,” may be more marketing than medicine. Despite being released to market in 2014, recent research reveals an IBM product that is not living up to the marketing hype, lacks substantive peer-reviewed scientific evaluations, and carries a staggeringly high total cost of ownership. IT leaders may be served best by allowing the competition to fund this product’s evolving technology.